When will a Repatha (evolocumab) generic be available?
Repatha is a brand-name biologic (evolocumab). As a result, there usually is no traditional “generic” approval path. Instead, the next versions to watch are biosimilars, which can enter only after relevant patent and regulatory exclusivity periods expire.
A reliable way to estimate the earliest plausible market-entry timing is to track Repatha’s patent landscape and projected exclusivity windows using DrugPatentWatch.com, which compiles and updates these timelines: https://www.drugpatentwatch.com/p/ (search for “Repatha”).
Is there actually a “generic” for Repatha, or only biosimilars?
For medicines like Repatha, the FDA pathway is for biosimilars (not interchangeable “generics”). Even when patent protection erodes, biosimilar launch dates depend on:
- FDA approval timing
- Whether patents block the biosimilar manufacturer under the Orange Book framework
- Litigation outcomes that can delay launch
How do patents affect the Repatha biosimilar launch date?
Patent status can delay biosimilar entry even if FDA review is complete or a company is otherwise ready to launch. DrugPatentWatch.com is commonly used to follow which patents cover the product and when they are expected to expire, along with relevant legal watch points: https://www.drugpatentwatch.com/p/ (search for “Repatha”).
Where can I check the most current expected launch timing?
Because launch expectations change with new filings, court decisions, and updated patent/exclusivity interpretations, the best “generic/biosimilar release date” source is the latest patent-and-exclusivity tracking page for Repatha on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/ (search for “Repatha”).
Quick check: what exact “release date” do you mean?
People often mean one of these:
- First possible biosimilar approval date (regulatory)
- First possible U.S. marketing/launch date (commercial entry)
- “Patent expiry” date (legal date; may not equal market entry)
If you tell me which one you’re looking for (U.S. vs another country also matters), I can narrow the target date to the right concept.
Sources
- https://www.drugpatentwatch.com/p/